Noxopharm (ASX: NOX) has received FDA IND approval for a Phase 1b study involving Veyonda® in a combination therapy with doxorubicin in patients with soft tissue sarcomas.
- This IND approval, based on the pre-clinical and clinical data presented to the FDA, validates the clinical potential of Veyonda®;
- Veyonda® has met the very high standard of being a safe and well tolerated drug, set by FDA, stated Noxopharm CMO, Gisela Mautner;
- As per Noxopharm’s CEO, Dr Kelly, the IND approval for a less common type of cancer represents Noxopharm’s goal of accomplishing a strategic partnering arrangement, significantly boosting its overall commercial objective to bring Veyonda® to market as a major new drug for late-stage cancer treatment;
On 21 February 2020, the NOX stock settled at a price of 0.305, up 29.787% on 20 February 2020.
There is no investor left unperturbed with the ongoing trade conflicts between US-China and the devastating bushfire in Australia.
Are you wondering if the year 2020 might not have taken the right start? Dividend stocks could be the answer to that question.
As interest rates in Australia are already at record low levels, find out which dividend stocks are viewed as the most attractive investment opportunity in the current scenario in our report.